Inversago Pharma

📍 Montreal, Canada👥 21 employees💰 Last funded Feb 2020
Biotechnology Research🌐 inversago.com
Website LinkedIn
Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
3
Investor activity2018–2020 · investors recorded per year
2018220201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Inversago Pharma?
Inversago Pharma has 3 investors on record on gritt.io.
When did Inversago Pharma last raise funding?
The most recent investment in Inversago Pharma recorded on gritt.io was in February 2020.
What industry is Inversago Pharma in?
Inversago Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Inversago Pharma based?
Inversago Pharma is headquartered in Montreal, Canada.